Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Mika Derynck sold 158,795 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the transaction, the director directly owned 87,373 shares in the company, valued at $5,260,728.33. This represents a 64.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Enliven Therapeutics Stock Performance
Enliven Therapeutics stock opened at $60.27 on Friday. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The business has a fifty day moving average of $48.21 and a two-hundred day moving average of $39.53. The company has a market cap of $3.67 billion, a P/E ratio of -36.09 and a beta of 0.27.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.57 EPS for the current year.
Analysts Set New Price Targets
View Our Latest Stock Analysis on ELVN
Enliven Therapeutics News Summary
Here are the key news stories impacting Enliven Therapeutics this week:
- Positive Sentiment: Encouraging clinical progress: Enliven reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, including encouraging efficacy and a favorable safety and tolerability profile. The company also said it reached agreement with the FDA on key components of the drug’s Phase 3 trial design. Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
- Positive Sentiment: Strong financial runway: Enliven ended the quarter with $895 million in cash, cash equivalents and marketable securities, which management expects to fund operations into 2030. This reduces near-term financing and dilution concerns for investors.
- Positive Sentiment: Analyst target increases: Goldman Sachs raised its price target from $67 to $80 and maintained a “buy” rating. Stifel Nicolaus also raised its target, from $80 to $82, while maintaining a “buy” rating. The revisions imply substantial upside from the stock’s recent trading level. Goldman Sachs price target update Stifel Nicolaus price target update
- Neutral Sentiment: Director sale: Director Mika K. Derynck sold 158,795 shares for approximately $9.6 million, reducing direct ownership by 64.5%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which may lessen concerns that the sale reflected a negative view of the company, although the transaction could still weigh on sentiment. SEC insider transaction filing
- Negative Sentiment: Quarterly loss exceeded expectations: Enliven reported a second-quarter loss of $0.49 per share, wider than the $0.39 loss analysts expected. The earnings miss contributed to an earlier pullback in the stock and highlights the company’s continuing lack of profitability. Enliven quarterly earnings release
Institutional Investors Weigh In On Enliven Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the period. Invesco Ltd. boosted its holdings in shares of Enliven Therapeutics by 4.3% in the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the period. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at $38,000. Finally, Swiss National Bank increased its holdings in shares of Enliven Therapeutics by 1.7% during the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after buying an additional 1,100 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
Enliven Therapeutics Company Profile
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
